Market cap
$3 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | 875.86 | 141.32 | -845.89 | -6.43 | -6.92 |
| Net Profit | 631.33 | 140.80 | -840.29 | -6.24 | -188.17 |
| EPS | 539.39 | 101.02 | 80.61 | 25.78 | 14.67 |
| Book Value | -- | -- | -99.49 | -88.31 | -75.55 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -10,173.95 | -748.06 | -- | -- | -- |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -64.85 | -51.77 | -221.89 | -123.95 | -21.59 |
| Return on Capital
| -64.21 | -51.24 | -- | -122.72 | -21.42 |
| Return on Assets
| -51.54 | -42.64 | -93.28 | -96.63 | -17.80 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.03 | 0.01 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
--
|
-122.72
|
-21.42
|
-48.50
|
-38.35
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-221.89
Lower than Peers by 195.58
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
-221.89
|
-123.95
|
-21.59
|
-49.02
|
-38.78
|
|
Peer Median
|
-26.31
|
--
|
--
|
--
|
--
|
ROA
-93.28
Lower than Peers by 80.31
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
-93.28
|
-96.63
|
-17.80
|
-40.19
|
-34.72
|
|
Peer Median
|
-12.96
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
--
|
--
|
--
|
-10,173.95
|
2,383.85
|
|
Peer Median
|
-59.70
|
--
|
--
|
--
|
--
|
Net Margin
--
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
--
|
--
|
--
|
-10,153.01
|
2,381.10
|
|
Peer Median
|
-71.06
|
--
|
--
|
--
|
--
|
Revenue Growth
--
--
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
--
|
--
|
-1.00
|
1.22
|
-1.84
|
|
Peer Median
|
20.56
|
--
|
--
|
--
|
--
|
EBIT Growth
-845.89
Lower than Peers by 861.09
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
-845.89
|
-265.47
|
63.67
|
8.17
|
-22.23
|
|
Peer Median
|
15.20
|
--
|
--
|
--
|
--
|
Net Profit Growth
-840.29
Lower than Peers by 848.15
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
-840.29
|
-264.45
|
63.58
|
8.25
|
-17.86
|
|
Peer Median
|
7.86
|
--
|
--
|
--
|
--
|
EPS Growth
80.61
Higher than Peers by 50.16
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
80.61
|
0.94
|
0.77
|
0.35
|
1.00
|
|
Peer Median
|
30.45
|
--
|
--
|
--
|
--
|
Book Value Growth
-99.03
Lower than Peers by 100.28
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
-99.03
|
--
|
--
|
--
|
--
|
|
Peer Median
|
1.25
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
--
|
0.03
|
0.01
|
0.01
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.01
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
0.01
|
0.03
|
0.01
|
0.01
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
3.70
Higher than Peers by 0.21
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
3.70
|
1.27
|
2.23
|
1.63
|
4.71
|
|
Peer Median
|
3.48
|
--
|
--
|
--
|
--
|
Quick Ratio
3.70
Higher than Peers by 0.41
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
3.70
|
--
|
--
|
--
|
--
|
|
Peer Median
|
3.29
|
--
|
--
|
--
|
--
|
Interest Coverage
-360.69
Lower than Peers by 359.18
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
-360.69
|
-678.28
|
-176.54
|
-355.73
|
-323.78
|
|
Peer Median
|
-1.51
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
--
|
--
|
--
|
104.70
|
--
|
|
Peer Median
|
24.33
|
--
|
--
|
--
|
--
|
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
--
|
--
|
--
|
0.00
|
-0.01
|
|
Peer Median
|
0.23
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
--
|
--
|
--
|
382.40
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
--
|
3,146.22
|
4,896.51
|
5,277.49
|
5,486,359.38
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
--
|
-0.30
|
-0.13
|
-0.01
|
-0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
0.22
Lower than Peers by 4.74
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
0.22
|
0.81
|
0.03
|
0.00
|
0.00
|
|
Peer Median
|
4.96
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-0.15
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
-0.15
|
0.06
|
1.05
|
0.76
|
1.46
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
3
Lower than Peers by 81
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
3
|
--
|
--
|
--
|
--
|
|
Peer Median
|
83
|
--
|
--
|
--
|
--
|